Colección SciELO Chile

Departamento Gestión de Conocimiento, Monitoreo y Prospección
Consultas o comentarios: productividad@anid.cl
Búsqueda Publicación
Búsqueda por Tema Título, Abstract y Keywords



Polygenic risk score of sporadic late-onset Alzheimer's disease reveals a shared architecture with the familial and early-onset forms
Indexado
Scopus SCOPUS_ID:85030027641
DOI 10.1016/J.JALZ.2017.08.013
Año 2018
Tipo

Citas Totales

Autores Afiliación Chile

Instituciones Chile

% Participación
Internacional

Autores
Afiliación Extranjera

Instituciones
Extranjeras


Abstract



Objective To determine whether the extent of overlap of the genetic architecture among the sporadic late-onset Alzheimer's Disease (sLOAD), familial late-onset AD (fLOAD), sporadic early-onset AD (sEOAD), and autosomal dominant early-onset AD (eADAD). Methods Polygenic risk scores (PRSs) were constructed using previously identified 21 genome-wide significant loci for LOAD risk. Results We found that there is an overlap in the genetic architecture among sEOAD, fLOAD, and sLOAD. The highest association of the PRS and risk (odds ratio [OR] = 2.27; P = 1.29 × 10−7) was observed in sEOAD, followed by fLOAD (OR = 1.75; P = 1.12 × 10−7) and sLOAD (OR = 1.40; P = 1.21 × 10−3). The PRS was associated with cerebrospinal fluid ptau181-Aβ42 on eADAD (P = 4.36 × 10−2). Conclusion Our analysis confirms that the genetic factors identified for LOAD modulate risk in sLOAD and fLOAD and also sEOAD cohorts. Specifically, our results suggest that the burden of these risk variants is associated with familial clustering and earlier onset of AD. Although these variants are not associated with risk in the eADAD, they may be modulating age at onset.

Revista



Revista ISSN
Alzheimers & Dementia 1552-5260

Métricas Externas



PlumX Altmetric Dimensions

Muestra métricas de impacto externas asociadas a la publicación. Para mayor detalle:

Disciplinas de Investigación



WOS
Clinical Neurology
Scopus
Sin Disciplinas
SciELO
Sin Disciplinas

Muestra la distribución de disciplinas para esta publicación.

Publicaciones WoS (Ediciones: ISSHP, ISTP, AHCI, SSCI, SCI), Scopus, SciELO Chile.

Colaboración Institucional



Muestra la distribución de colaboración, tanto nacional como extranjera, generada en esta publicación.


Autores - Afiliación



Ord. Autor Género Institución - País
1 Cruchaga, Carlos Hombre Washington University School of Medicine in St. Louis - Estados Unidos
2 Del-Aguila, Jorge L. Hombre Washington University School of Medicine in St. Louis - Estados Unidos
3 Saef, Benjamin Hombre Washington University School of Medicine in St. Louis - Estados Unidos
4 Black, Kathleen Mujer Washington University School of Medicine in St. Louis - Estados Unidos
5 Fernandez, Maria Victoria Mujer Washington University School of Medicine in St. Louis - Estados Unidos
6 Budde, John Hombre Washington University School of Medicine in St. Louis - Estados Unidos
7 Ibanez, Laura Mujer Washington University School of Medicine in St. Louis - Estados Unidos
8 Deming, Yuetiva - Washington University School of Medicine in St. Louis - Estados Unidos
9 Kapoor, Manav - Icahn School of Medicine at Mount Sinai - Estados Unidos
10 Tosto, Giuseppe Hombre Vagelos College of Physicians and Surgeons - Estados Unidos
Gertrude H. Sergievsky Center - Estados Unidos
11 Mayeux, Richard Hombre Vagelos College of Physicians and Surgeons - Estados Unidos
Gertrude H. Sergievsky Center - Estados Unidos
Pontificia Universidad Católica de Chile - Chile
12 Holtzman, David M. Hombre Washington University School of Medicine in St. Louis - Estados Unidos
13 Fagan, Anne M. Mujer Washington University School of Medicine in St. Louis - Estados Unidos
14 Morris, J. C. Hombre Washington University School of Medicine in St. Louis - Estados Unidos
15 Bateman, Randall J. Hombre Washington University School of Medicine in St. Louis - Estados Unidos
16 Goate, Alison M. Mujer Icahn School of Medicine at Mount Sinai - Estados Unidos
17 Harari, Oscar Hombre Washington University School of Medicine in St. Louis - Estados Unidos

Muestra la afiliación y género (detectado) para los co-autores de la publicación.

Financiamiento



Fuente
National Institutes of Health
NIH Roadmap for Medical Research
Medical Research Council
Canadian Institutes of Health Research
Alzheimer's Association
Bristol-Myers Squibb
National Cancer Institute
Servier
Eisai
Foundation for the National Institutes of Health
National Institute on Aging
AbbVie
U.S. Department of Defense
Pfizer
Merck
American Federation for Aging Research
Eli Lilly and Company
Genentech
F. Hoffmann-La Roche
National Center for Research Resources
GE Healthcare
Biogen
National Institute of Biomedical Imaging and Bioengineering
Euroimmun
Lundbeckfonden
Washington University School of Medicine in St. Louis
Takeda Pharmaceutical Company
Novartis Pharmaceuticals Corporation
Siteman Cancer Center
Alzheimer's Disease Research Foundation
Lumosity
Piramal Imaging
Neurotrack Technologies
Cogstate
Elan Pharmaceuticals, Inc.
IXICO Ltd.
CereSpir, Inc.
NeuroRx Research
Transition Therapeutics
Alzheimer's Drug Discovery Foundation
Janssen Alzheimer Immunotherapy Research & Development, LLC.
Araclon Biotech
NCI Cancer Center Support
DOD ADNI
Deutsches Zentrum für Neurodegenerative Erkrankungen
DIAN-TU Pharma Consortium
ADNI clinical sites in Canada
BioClinica
ICTS/CTSA
Dominantly Inherited Alzheimer Network
Johnson & Johnson Pharmaceutical Research & Development LLC.
Fujirebio US
NIHR Queen Square Dementia Biomedical Research Unit
MRC Dementias Platform UK
Meso Scale Diagnostics, LLC.
Alzheimer's Disease Neuroimaging Initiative
Hope Center for Neurological Disorders
German Center for Neurodegenerative Diseases
Institute of Clinical and Translational Sciences
Georgia Clinical and Translational Science Alliance
BrightFocus Foundation Alzheimer's Disease Research
Alvin J. Siteman Cancer Center
DIAN-TU

Muestra la fuente de financiamiento declarada en la publicación.

Agradecimientos



Agradecimiento
Data collection and sharing for this project were funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense, award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie; Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd. and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health ( www.fnih.org ). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California.

Muestra la fuente de financiamiento declarada en la publicación.